
Icotrokinra results show significant skin clearance in patients with difficult to treat scalp, genital psoriasis: JnJ
Spring House: Johnson & Johnson has announced new data from the Phase 3 ICONIC-TOTAL study investigating icotrokinra (JNJ-2113), the first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor. The study evaluated …